TAMPA, Fla., Nov. 30 /PRNewswire/ -- Tenby Pharma Inc. announced today that it has changed its corporate name to Sirion Holdings, Inc. This comes after a recent transaction whereby Sirion Therapeutics, Inc. became a wholly owned subsidiary of Tenby. From Tenby Pharma’s inception until the consummation of the Sirion acquisition, Tenby Pharma was a shell company with no business or operations and only nominal assets. Pursuant to the transaction, Sirion’s former stockholders acquired control of Tenby Pharma and Tenby Pharma became the parent holding company for Sirion and its businesses. Additionally, in connection with the transaction, Tenby Pharma secured $25 million in financing from a group of affiliated institutional investors to develop and commercialize the Sirion portfolio of products.
“With the acquisition and change of control, Tenby ceased to operate as a shell company. We believe that the new name more effectively identifies our post-transaction company with the name and brand of our primary business and operating subsidiary, Sirion Therapeutics, Inc.,” said Susan Benton, Chief Commercial Officer of Sirion Therapeutics.
About Sirion Holdings and Sirion Therapeutics, Inc.
Sirion Holdings, Inc. is a holding company for Sirion Therapeutics, Inc. Sirion Therapeutics is a Tampa, Florida based biopharmaceutical company, with additional offices in La Jolla, California, dedicated to the development and commercialization of innovative ophthalmic products. For more information regarding Sirion and the matters announced in this press release, please visit Sirion’s website at www.siriontherapeutics.com and see Sirion’s public filings with the Securities and Exchange Commission, which may be obtained free of charge.
Sirion Holdings, Inc.
CONTACT: Penny Cobb of Sirion, +1-813-496-7325 x221, orpcobb@siriontherapeutics.com
Web site: http://www.siriontherapeutics.com/